MX2018006103A - Encapsulacion de analogos de insulina ultra-estables dentro de materiales fundidos de polimero. - Google Patents

Encapsulacion de analogos de insulina ultra-estables dentro de materiales fundidos de polimero.

Info

Publication number
MX2018006103A
MX2018006103A MX2018006103A MX2018006103A MX2018006103A MX 2018006103 A MX2018006103 A MX 2018006103A MX 2018006103 A MX2018006103 A MX 2018006103A MX 2018006103 A MX2018006103 A MX 2018006103A MX 2018006103 A MX2018006103 A MX 2018006103A
Authority
MX
Mexico
Prior art keywords
insulin analogue
insulin
amino
beta
polymer blend
Prior art date
Application number
MX2018006103A
Other languages
English (en)
Inventor
Weiss Michael
Pokorski Jon
Original Assignee
Univ Case Western Reserve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Case Western Reserve filed Critical Univ Case Western Reserve
Publication of MX2018006103A publication Critical patent/MX2018006103A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición de insulina comprende un análogo de insulina y mezcla de polímero. El análogo de insulina contiene sustituciones de Cisteína en las posiciones B4 y A10 (para formar cistina B4-A10), y una o más sustituciones adicionales seleccionadas del grupo que consiste de: un dominio de conexión de 5-11 aminoácidos entre los dominios A y B de insulina; una sustitución de aminoácido no-beta-ramificada en la posición A8; una cadena lateral acídica o polar no-beta-ramificada en la posición A14; una modificación halogénica de PheB24 en la posición orto; y una sustitución de lisina en la posición B29 por Glu, Ala, Val, IIe, Leu, ácido amino-propiónico, ácido amino-butírico o Norleucina. El análogo de insulina es compatible con un proceso de manufactura que incluye uno o más etapas dentro del intervalo de temperatura de 90-120°C. El análogo de insulina encapsulado opcionalmente puede contener PEG puro o ser PEGilado. La mezcla de polímero que encapsula el análogo de insulina se puede fundir o moldear como un parche de microagujas para administración tópica o como micropelotillas para inyección subcutánea.
MX2018006103A 2015-12-23 2016-12-23 Encapsulacion de analogos de insulina ultra-estables dentro de materiales fundidos de polimero. MX2018006103A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562387459P 2015-12-23 2015-12-23
PCT/US2016/068572 WO2017112952A1 (en) 2015-12-23 2016-12-23 Encapsulation of ultra-stable insulin analogues with polymer melts

Publications (1)

Publication Number Publication Date
MX2018006103A true MX2018006103A (es) 2018-09-21

Family

ID=59091272

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006103A MX2018006103A (es) 2015-12-23 2016-12-23 Encapsulacion de analogos de insulina ultra-estables dentro de materiales fundidos de polimero.

Country Status (15)

Country Link
US (1) US11583572B2 (es)
EP (1) EP3393498A4 (es)
JP (1) JP7203415B2 (es)
KR (1) KR20180097517A (es)
CN (1) CN108430493A (es)
AU (2) AU2016377786A1 (es)
BR (1) BR112018012814A2 (es)
CA (1) CA3009187A1 (es)
EA (1) EA039101B1 (es)
HK (1) HK1255634A1 (es)
IL (1) IL259899A (es)
MX (1) MX2018006103A (es)
PH (1) PH12018500966A1 (es)
SG (1) SG11201803911PA (es)
WO (1) WO2017112952A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR111122A1 (es) * 2017-03-07 2019-06-05 Univ Case Western Reserve Análogos de insulina de cadena única estabilizados por un cuarto puente disulfuro
US20210371489A1 (en) * 2018-09-21 2021-12-02 Case Western Reserve University Site 2 single-chain insulin analogues
CN113330025A (zh) * 2018-11-19 2021-08-31 卡斯西部储备大学 具有聚丙氨酸c结构域子区段的单链胰岛素类似物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102816228A (zh) 2003-12-03 2012-12-12 诺和诺德公司 单链胰岛素
WO2007081824A2 (en) * 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
EP1991575A1 (en) 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
KR20110021758A (ko) * 2008-04-22 2011-03-04 케이스 웨스턴 리저브 유니버시티 이형체-특이적 인슐린 유사체
KR20110061552A (ko) * 2008-07-31 2011-06-09 케이스 웨스턴 리저브 유니버시티 할로겐 안정화된 인슐린
US8815798B2 (en) 2010-06-23 2014-08-26 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
MX337549B (es) * 2010-06-23 2016-03-10 Novo Nordisk As Derivados de insulina que contienen enlaces disulfuro adicionales.
WO2013010048A2 (en) 2011-07-13 2013-01-17 Case Western Reserve University Non-standard insulin analogues
US9101547B2 (en) * 2011-08-04 2015-08-11 Nano And Advanced Materials Institute Limited Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
AU2012328407A1 (en) * 2011-10-27 2014-05-22 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations
ES2694418T3 (es) * 2012-11-05 2018-12-20 Case Western Reserve University Análogos de insulina de cadena sencilla de acción prolongada
EP3024447A1 (en) * 2013-07-24 2016-06-01 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and an anionic copolymer coating
EP3204410B1 (en) * 2014-10-06 2021-01-20 Case Western Reserve University Biphasic single-chain insulin analogues
AR111122A1 (es) * 2017-03-07 2019-06-05 Univ Case Western Reserve Análogos de insulina de cadena única estabilizados por un cuarto puente disulfuro

Also Published As

Publication number Publication date
WO2017112952A1 (en) 2017-06-29
JP2019503339A (ja) 2019-02-07
PH12018500966A1 (en) 2018-11-19
AU2016377786A1 (en) 2018-06-14
US11583572B2 (en) 2023-02-21
KR20180097517A (ko) 2018-08-31
JP7203415B2 (ja) 2023-01-13
SG11201803911PA (en) 2018-07-30
CN108430493A (zh) 2018-08-21
EP3393498A1 (en) 2018-10-31
AU2021245176A1 (en) 2021-11-04
BR112018012814A2 (pt) 2018-12-04
EA039101B1 (ru) 2021-12-03
WO2017112952A4 (en) 2017-08-17
HK1255634A1 (zh) 2019-08-23
IL259899A (en) 2018-07-31
EA201891474A1 (ru) 2018-12-28
EP3393498A4 (en) 2019-08-07
CA3009187A1 (en) 2017-06-29
US20210162014A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
PH12018500966A1 (en) Encapsulation of ultra-stable insulin analogues with polymer melts
EA201892737A1 (ru) ИНЪЕКЦИОННЫЙ РАСТВОР ПРИ pH 7, ВКЛЮЧАЮЩИЙ ПО МЕНЬШЕЙ МЕРЕ ОДИН БАЗАЛЬНЫЙ ИНСУЛИН, pI КОТОРОГО ИМЕЕТ ЗНАЧЕНИЕ ОТ 5,8 ДО 8,5, И СОПОЛИАМИНОКИСЛОТУ, НЕСУЩУЮ КАРБОКСИЛАТНЫЕ ЗАРЯДЫ И ГИДРОФОБНЫЕ РАДИКАЛЫ
AR111122A1 (es) Análogos de insulina de cadena única estabilizados por un cuarto puente disulfuro
EA201490913A1 (ru) Лекарственные формы для лечения сахарного диабета
PH12018500690A1 (en) Novel insulin analogs and use thereof
EA201790871A1 (ru) Нацеленные конъюгатные композиции xten и способы их получения
EA201391756A1 (ru) Композиции, содержащие, способы, включающие, и применение производных доластатина, связанных с неприродными аминокислотами
MX2015017274A (es) Moduladores del receptor del polipéptido insulina estabilizados.
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
WO2015048498A3 (en) Carrier-free biologically-active protein nanostructures
NZ612312A (en) Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota
MX2017012270A (es) Composiciones sinergicas de acido dehidroacetico y metodos para reducir el amarillamiento en varias composiciones de usuario final.
RU2012157683A (ru) Производные инсулина, содержащие дополнительные дисульфидные связи
BR112016020181A8 (pt) composições de ácido lipoico éster colina e métodos de uso.
MX2012007416A (es) Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis.
MY181626A (en) Treatment of diabetes mellitus by long-acting formulations of insulins
PH12017500098A1 (en) Suspension compositions of cyclosporin a for subconjunctival and periocular injection
MX371328B (es) Constructo de fusion de la fraccion efectora del fragmento de union a antigeno (fab) de anti-albumina de suero y su metodo de preparacion.
ATE498222T1 (de) Verfahren zur herstellung eines elektrischen hybridbauteils
MY181399A (en) Multifunctional benzoxazines and composite materials incorporating the same
JOP20180052A1 (ar) تغليف مضاهئات إنسولين فائقة الاستقرار داخل فلزات بوليمرية
BR112012017093A2 (pt) compostos orgânicos para a regulação de canais de íons vetoriais
WO2014153381A8 (en) Alpha-lactalbumin enriched whey protein compositions and methods of making and using them
WO2014058329A8 (de) Kompositionen auf basis von hormonen der hypophyse, zur zugabe in infusionsflüssigkeiten